Purchase this article with an account.
T. Kaburaki, A. Yoshida, S. Fujimura, K. Akiyama, J. Numaga, Y. Fujino, H. Kawashima; Adverse Effects of Topical Latanoprost on Experimental Autoimmune Uveitis . Invest. Ophthalmol. Vis. Sci. 2003;44(13):723.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Because of the controversy surrounding possible adverse side effects as a result of topical latanoprost (Lat), anti-glaucoma eyedrop of prostaglandin F2a analog, usage on patients with uveitis, we examined the influence of topical Lat on the severity of experimental autoimmune uveitis (EAU) in rats. Methods: EAU was induced with 50µg of S-Ag peptide in Lewis rats. Sixty rats were divided into four groups (Group1: benzalkonium chloride (vehicle) only, Group2: Lat, Group3: Dexamethazone (DEX)+vehicle, Group4: DEX+Lat, each n=15). 10µl of eyedrop was applied each time. Dex was applied twice a day, Lat and vehicle were applied once a day. The onset and severity of EAU were monitored with a slit lamp everyday and evaluated by the combined EAU score (0-4 in each eye) of both eyes. Results: The average days of the onsets of EAU were 9.8±0.9, 10.4±1.1, 16.3±3.9, and 14.7±2.2 in Groups 1-4, respectively. The peak of EAU was observed on day 12, 12, 16, and 17, respectively . The peak values of the EAU score were 7.1±0.2, 6.1±0.6, 3.0±0.8, and 3.3±0.7 (average ± standard error ), respectively. There were no significant differences of the onset day and the peak values of EAU score in Group 1 vs Group 2, and in Group 3 vs Group 4. Conclusions: Obvious adverse side effects of topical latanoprost on EAU were not detected clinically in this study. Pathological examinations are currently in progress to further elucidate the issue.
This PDF is available to Subscribers Only